Physician profile
Albert Digerolamo
NPI 1427069871
$933.79
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $143 · 2023: $22.83 · 2024: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $389.52 | 2019-2024 | Breztri, Airsupra |
| Novo Nordisk INC | $65.46 | 2019-2020 | |
| Abbvie INC. | $64.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.57 | 2019-2020 | |
| Amgen INC. | $46.88 | 2019 | |
| Merck Sharp & Dohme LLC | $46.15 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $41.06 | 2019 | |
| Astellas Pharma US INC | $30.74 | 2019 | |
| Lilly USA, LLC | $25.95 | 2019-2020 | |
| Gilead Sciences, INC. | $24.55 | 2019 | |
| Dexcom, INC. | $22.83 | 2023 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $17.40 | 2019 | |
| Sanofi Pasteur INC. | $15.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.23 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $12.38 | 2019 | |
| Pfizer INC. | $12.22 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.72 | 2020 | |
| Hikma Pharmaceuticals USA | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Digerolamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.